About this item:

91 Views | 49 Downloads

Author Notes:

Correspondence to: Dr Mianhua Wu or Dr Xu Zhang, Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine (TCM) Prevention and Treatment of Tumors, Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210023, P.R. China E-mail: wmh7001@163.com E-mail: zhangxu@njucm.edu.cn

XZ, HF and MW conceived and designed the study.

MC, CH, RJ, YG, HJ and YZ performed the experiments. MC wrote the manuscript.

All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

The authors thank Professor Zhigang Tu (Jiangsu University, China) for providing the EA.hy926 cell line.

All the above experiments in mice were carried out in strict accordance with the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health.

Our protocol was approved by the Committee on the Ethics of Animal Experiments of Nanjing University of Chinese Medicine.

The authors declare that they have no competing interests.

Subjects:

Research Funding:

The present study was supported by the National Natural Science Foundation of China (grant no. 81503374), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), the Natural Science Foundation of Jiangsu Province (grant no. BK20151003) and the Research Foundation of Education Bureau of Jiangsu Province (grant no. 16KJA360001).

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Oncology
  • Ophiopogonin B
  • epithelial-mesenchymal transition
  • metastasis
  • angiogenesis
  • adenocarcinoma
  • EphA2
  • Akt
  • LUNG-CANCER
  • RECEPTOR
  • PROLIFERATION
  • EXPRESSION
  • AUTOPHAGY
  • DIAGNOSIS
  • EPHRINA1
  • MOTILITY
  • LIGAND
  • SRC

Ophiopogonin B suppresses the metastasis and angiogenesis of A549 cells in vitro and in vivo by inhibiting the EphA2/Akt signaling pathway

Tools:

Journal Title:

Oncology Reports

Volume:

Volume 40, Number 3

Publisher:

, Pages 1339-1347

Type of Work:

Article | Final Publisher PDF

Abstract:

Lung adenocarcinoma is the most common metastatic cancer, and is associated with high patient mortality. Therefore, investigation of anti-metastatic treatments for lung adenocarcinoma is crucial. Ophiopogonin B (OP-B) is a bioactive component of Radix Ophiopogon Japonicus, which is often used in Chinese traditional medicine to treat pulmonary disease. Screening of transcriptome and digital gene expression (DGE) profiling data in NSCLC cell lines showed that OP-B regulated the epithelial-mesenchymal transition (EMT) pathway in A549 cells. Further results showed that 10 µmol/l OP-B downregulated EphA2 expression and phosphorylation (Ser897) in A549 cells but upregulated them in NCI-H460 cells. Meanwhile, the Ras/ERK pathway was unaffected in A549 cells and stimulated in NCI-H460 cells. More importantly, detection of the EMT pathway showed that OP-B treatment increased the epithelial markers ZO-1 and E-cadherin and decreased the expression of the mesenchymal marker N-cadherin and the transcriptional repressors Snail, Slug and ZEB1. Furthermore, through Transwell migration and scratch wound healing assays, we found that 10 µmol/l OP-B significantly reduced the invasion and migration of A549 cells. In vivo, we found that 75 mg/kg OP-B inhibited A549 cell metastasis in a pulmonary metastasis nude mouse model. In addition, we also found that 10 µmol/l OP-B significantly inhibited tube formation in EA.hy926 cells.

Copyright information:

© Chen et al.

This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Creative Commons License

Export to EndNote